Stoke Therapeutics’ (STOK) Buy Rating Reiterated at Canaccord Genuity

Share on StockTwits

Canaccord Genuity restated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note issued to investors on Friday morning, TipRanks reports. Canaccord Genuity currently has a $44.00 target price on the stock.

Several other research analysts also recently commented on the stock. Zacks Investment Research raised shares of Stoke Therapeutics from a hold rating to a buy rating and set a $30.00 price target on the stock in a research note on Thursday, May 28th. HC Wainwright reaffirmed a buy rating and issued a $30.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 18th. BidaskClub raised shares of Stoke Therapeutics from a sell rating to a hold rating in a research note on Tuesday, May 12th. Cowen reaffirmed a buy rating on shares of Stoke Therapeutics in a research note on Monday, March 23rd. Finally, ValuEngine raised shares of Stoke Therapeutics from a hold rating to a buy rating in a research report on Thursday, April 2nd. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $35.57.

STOK stock opened at $23.65 on Friday. The company has a market capitalization of $779.81 million and a PE ratio of -13.14. Stoke Therapeutics has a 12 month low of $15.82 and a 12 month high of $39.04. The firm’s 50-day moving average is $25.38 and its 200 day moving average is $24.57.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. As a group, analysts predict that Stoke Therapeutics will post -1.52 earnings per share for the current fiscal year.

In other news, insider Barry Ticho sold 1,365 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $27.39, for a total value of $37,387.35. Following the transaction, the insider now owns 131,147 shares of the company’s stock, valued at approximately $3,592,116.33. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gene Liau sold 7,500 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $30.00, for a total transaction of $225,000.00. Following the completion of the transaction, the executive vice president now directly owns 21,000 shares in the company, valued at approximately $630,000. The disclosure for this sale can be found here. Insiders have sold a total of 30,972 shares of company stock worth $846,656 in the last three months. Insiders own 54.60% of the company’s stock.

Several institutional investors have recently modified their holdings of STOK. Redmile Group LLC grew its position in shares of Stoke Therapeutics by 112.2% in the 1st quarter. Redmile Group LLC now owns 2,165,938 shares of the company’s stock worth $49,600,000 after buying an additional 1,145,160 shares during the last quarter. BlackRock Inc. grew its position in shares of Stoke Therapeutics by 49.1% in the 1st quarter. BlackRock Inc. now owns 1,370,786 shares of the company’s stock worth $31,391,000 after buying an additional 451,363 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in shares of Stoke Therapeutics in the 1st quarter worth approximately $4,178,000. Victory Capital Management Inc. boosted its stake in Stoke Therapeutics by 4,491.1% in the 4th quarter. Victory Capital Management Inc. now owns 179,648 shares of the company’s stock worth $5,088,000 after purchasing an additional 175,735 shares in the last quarter. Finally, State Street Corp boosted its stake in Stoke Therapeutics by 73.4% in the 1st quarter. State Street Corp now owns 294,281 shares of the company’s stock worth $6,739,000 after purchasing an additional 124,537 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

See Also: How to Trade Using Analysts Ratings

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.